新诊断罕见自身免疫性疾病的患者好消息:研究发现低复发风险
Good news for people newly diagnosed with rare autoimmune disorder: Study finds low relapse risk
一项Kaiser Permanente研究发现,新诊断为MOGAD的患者复发风险低,80%以上完全康复,仅少数患者出现复发或严重后遗症。
研究显示MOGAD患者复发风险低,为新诊断患者带来希望。
People newly diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, generally had a low risk of relapse and lasting disability, according to a Kaiser Permanente study. The work is published in the journal Neurology.
Researchers from Kaiser Permanente in Southern California followed 69 children and adults diagnosed at their first MOGAD attack and found that more than 80% fully recovered, while just under 12% experienced a relapse during a median follow-up of about 32 months. MOGAD is a rare inflammatory disease of the central nervous system that can affect the brain, spinal cord and optic nerves and cause severe neurological symptoms.
The findings provide a more reassuring picture of MOGAD than previous research, which has often estimated that 40% to 50% of patients experience a relapse. In the new study, 57 of 69 patients fully recovered, only eight experienced another attack, and three were left with moderate-to-severe lasting deficits. The low relapse rate occurred even though relatively few patients received preventive immunotherapy or prolonged corticosteroid treatment.
"The diagnosis of MOGAD can be frightening because the first attack can cause serious neurological symptoms," said lead author Annette M. Langer-Gould, M.D., Ph.D., a neuroimmunologist at the Kaiser Permanente Los Angeles Medical Center and an epidemiologist and researcher. "One of the biggest questions after a first MOGAD attack is what the future will look like for that patient."
"Our findings suggest that for most patients, the outlook is encouraging, with a high likelihood of full recovery and a relatively low risk of another attack," said Langer-Gould.
MOGAD has only recently been recognized as a distinct neurological disease. Previous estimates of relapse risk often came from specialized referral centers that may have disproportionately included people with recurrent or more severe disease.
The new study instead examined a contemporary, population-based group of Kaiser Permanente Southern California patients starting with their first recognized attack, providing a clearer picture of recovery and recurrence after an initial diagnosis.
Researchers said larger studies are still needed to identify which patients are at greater risk of relapse and to determine the optimal length of treatment in the people with MOGAD who do experience a subsequent relapse.
Publication details
Annette Langer-Gould et al., Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Relapse Risk in a Contemporary, Population-based Cohort (S6.008), Neurology (2026). DOI: 10.1212/wnl.0000000000215612
Journal information: Neurology
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Good news for people newly diagnosed with rare autoimmune disorder: Study finds low relapse risk (2026, November 10) retrieved 10 November 2026 from https://medicalxpress.com/news/2026-11-good-news-people-newly-rare.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com